Structure of Benzyl alcohol
CAS No.: 100-51-6
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Benzyl Alcohol is a monoaromatic primary alcohol widely used as a solvent and as an intermediate in cosmetic formulations, pharmaceutical and flavor/fragrance industries.
Synonyms: Benzenemethanol
4.5
*For Research Use Only !
Change View
| Size | Price | VIP Price |
DE Stock US Stock |
Asia Stock Global Stock |
In Stock |
| {[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | {[ item.p_spot_brand_remark ]} 1-2 weeks {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.p_spot_brand_remark ]} 1-2 weeks {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock Inquiry - | Login - + |
Please Login or Create an Account to: See VIP prices and availability
Asia Stock: Ship in 3-5 business days
EU Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
{[ item.p_spot_brand_remark ]}
1-2weeks
Inquiry
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ item.p_spot_brand_remark ]}
1-2weeks
Inquiry
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
Asia Stock: Ship in 3-5 business days
EU Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Joanna Klimek ; Oskar Kruc ; Joanna Ceklarz ; Beata Kami ´nska ; Bogdan Musielak ; Robin van der Straat , et al.
Abstract: The PD-1/PD-L1 complex is an immune checkpoint responsible for regulating the natural immune response, but also allows tumors to escape immune surveillance. Inhibition of the PD-1/PD-L1 axis positively contributes to the efficacy of cancer treatment. The only available therapeutics targeting PD-1/PD-L1 are monoclonal antibody-based drugs, which have several limitations. Therefore, small molecule compounds are emerging as an attractive alternative that can potentially overcome the drawbacks of mAb-based therapy. In this article, we present a novel class of small molecule compounds based on the terphenyl scaffold that bind to PD-L1. The general architecture of the presented structures is characterized by axial symmetry and consists of three elements: an m-terphenyl core, an additional aromatic ring, and a solubilizing agent. Using molecular docking, we designed a series of final compounds, which were subsequently synthesized and tested in HTRF assay and NMR binding assay to evaluate their activity. In addition, we performed an in-depth analysis of the mutual arrangement of the phenyl rings of the terphenyl core within the binding pocket of PD-L1 and found several correlations between the plane angle values and the affinity of the compounds towards the protein.
Show More >
Keywords: PD-L1 ; immune checkpoint ; small molecule inhibitor ; cancer ; C2-symmetrical ligands
Show More >
Surveying the scope of aromatic decarboxylations catalyzed by prenylated-flavin dependent enzymes
Anushree Mondal ; Pronay Roy ; Jaclyn Carrannatto ; Prathamesh M. Datar ; Daniel J. DiRocco ; Katherine Huntera and E. Neil G. Marsh
Abstract: The prenylated-flavin mononucleotide-dependent decarboxylases (also known as UbiD-like enzymes) are the most recently discovered family of decarboxylases. The modified flavin facilitates the decarboxylation of unsaturated carboxylic acids through a novel mechanism involving 1,3-dipolar cyclo-addition chemistry. UbiD-like enzymes have attracted considerable interest for biocatalysis applications due to their ability to catalyse (de)carboxylation reactions on a broad range of aromatic substrates at otherwise unreactive carbon centres. There are now ∼35[thin space (1/6-em)]000 protein sequences annotated as hypothetical UbiD-like enzymes. Sequence similarity network analyses of the UbiD protein family suggests that there are likely dozens of distinct decarboxylase enzymes represented within this family. Furthermore, many of the enzymes so far characterized can decarboxylate a broad range of substrates. Here we describe a strategy to identify potential substrates of UbiD-like enzymes based on detecting enzyme-catalysed solvent deuterium exchange into potential substrates. Using ferulic acid decarboxylase (FDC) as a model system, we tested a diverse range of aromatic and heterocyclic molecules for their ability to undergo enzyme-catalysed H/D exchange in deuterated buffer. We found that FDC catalyses H/D exchange, albeit at generally very low levels, into a wide range of small, aromatic molecules that have little resemblance to its physiological substrate. In contrast, the sub-set of aromatic carboxylic acids that are substrates for FDC-catalysed decarboxylation is much smaller. We discuss the implications of these findings for screening uncharacterized UbiD-like enzymes for novel (de)carboxylase activity.
Show More >
Purchased from AmBeed: 27916-43-4 ; 2438-05-3 ; 501-89-3 ; 42287-94-5 ; 776-79-4 ; 53473-36-2 ; 7251-61-8 ; 42287-97-8 ; 1621-91-6 ; 37718-11-9 ; 288-13-1 ; 86-73-7 ; 104-53-0 ; 2018-90-8 ; 87-66-1 ; 135-19-3 ; 1664-57-9 ; 289-80-5 ; 693-95-8 ; 55-22-1 ; 102-93-2 ; 1477-50-5 ; 1632-76-4 ; 4780-79-4 ; 16642-79-8 ; 3581-89-3 ; 501-97-3 ; 771-50-6 ; 98-98-6 ; 619-64-7 ; 100-51-6 ; 402-45-9 ; 59-67-6 ; 93-60-7 ; 273-53-0 ; 2084-13-1 ; 51-17-2 ; 2459-09-8 ; 2459-07-6 ; 95-16-9 ; 459-31-4 ; 90-05-1 ; 150-76-5 ; 103-25-3 ; 271-44-3 ; 6293-56-7 ; 2550-26-7 ; 288-32-4 ; 501-52-0 ; 2001-32-3 ; 1592-38-7 ; 95-15-8 ; 91-19-0 ; 1122-61-8 ; 3724-19-4 ; 20173-24-4 ; 118-31-0 ; 6125-24-2 ; 60-12-8 ; 90-15-3 ; 120-72-9 ; 822-36-6 ; 288-47-1 ; 288-42-6 ; 2038-57-5 ; 38628-51-2 ; 1929-29-9 ; 15009-91-3 ; 1505-50-6 ; 581-40-8 ; 616-47-7 ; 1571-33-1
Show More >
| CAS No. : | 100-51-6 |
| Formula : | C7H8O |
| M.W : | 108.14 |
| SMILES Code : | OCC1=CC=CC=C1 |
| Synonyms : |
Benzenemethanol
|
| MDL No. : | MFCD00004599 |
| InChI Key : | WVDDGKGOMKODPV-UHFFFAOYSA-N |
| Pubchem ID : | 244 |
| GHS Pictogram: |
|
| Signal Word: | Warning |
| Hazard Statements: | H302-H315-H319-H335 |
| Precautionary Statements: | P261-P305+P351+P338 |
| Description |
Benzyl alcohol is an aromatic alcohol with a mild aromatic odor and acts as an inhibitor of the P450 enzyme. It modulates the Toll-Like Receptor 4, thereby reducing the inflammatory response associated with liver injury in mice[1].[2].[3].
|
Clinical Trial:
| NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
| NCT00795678 | - | Completed | - | United States, New York ... More >> Memorial Sloan Kettering New York, New York, United States, 10065 United States, Ohio Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44195 Less << | |
| NCT00787761 | Myeloproliferative Disorders ... More >> Kidney Cancer Leukemia Lymphoma Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Diseases Less << | Phase 2 | Completed | - | United States, Georgia ... More >> Blood and Marrow Transplant Group of Georgia Atlanta, Georgia, United States, 30342 Less << |
| NCT02340962 | Hepatitis C, Chronic | Phase 2 | Completed | - | Taiwan ... More >> Kaohsiung Medical University Chung-Ho Memorial Hospital Kaohsiung, Taiwan Less << |
| NCT02340962 | - | Completed | - | - | |
| NCT02798523 | Normal Physiology | Phase 1 | Recruiting | August 1, 2023 | United States, Maryland ... More >> National Institutes of Health Clinical Center Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) 800-411-1222 ext TTY8664111010 prpl@cc.nih.gov Less << |
| NCT03566069 | Depression, Anxiety | Phase 2 | Not yet recruiting | December 2021 | - |
| NCT00356200 | - | Terminated(Enrollment criteria... More >> met) Less << | - | - | |
| NCT00637962 | HIV Infections ... More >> Acquired Immune Deficiency Syndrome Less << | Phase 1 | Terminated(IMP expired prior t... More >>o completion of recruitment) Less << | - | United Kingdom ... More >> St George's Vaccine Institute London, England, United Kingdom, SW17 0RE York Hospital York, England, United Kingdom, YO31 7WA Less << |
| NCT03117816 | Chronic Myeloid Leukemia in Re... More >>mission Less << | Phase 2 | Recruiting | December 2024 | Germany ... More >> Universitätsklinikum Aachen Recruiting Aachen, Germany, 52074 Contact: Martina Crysant, MD ++49 241 80 ext 80591 mcrysandt@ukaachen.de Contact: Tim H. Brümmendorf, Prof ++49 241 80 ext 89805 tbruemmendorf@ukaachen.de Principal Investigator: Martina Crysant, MD Studienzentrum Aschaffenburg Recruiting Aschaffenburg, Germany, 63739 Contact: Martine Klausmann, MD ++49 6021-342 ext 780 mk@klausmann.de Contact: Silke Schirrmacher-Memmel, MD ++49 6021-342 ext 780 sm@klausmann.de Universitätsmedizin Berlin Charite- Campus Virchow Klinikum Recruiting Berlin, Germany, 13353 Contact: Philipp Le Courte, MD ++49 30 450 665 ext 307 philipp.lecoutre@charite.de Contact: Theo Kim, MD ++49 30 450 ext 513077 theo.kim@charite.de Principal Investigator: Philipp Le Courte, MD Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik III Recruiting Bonn, Germany, 53105 Contact: Jai-Jün Shiue, MD ++49 228 287 17 ext 233 jai-juen.shiue@ukb.uni-bonn.de Contact: Lino Teichmann, MD 0228-287 51 ext 630 lino.teichmann@ukb.uni-bonn.de Klinikum Bremen Mitte, Medizinische Klinik I Recruiting Bremen, Germany, 28177 Contact: Matthias Bormann, Dr.med. ++49 421 497 ext 5132 matthias.bormann@klinikum-bremen-mitte.de Contact: Bernd Hertenstein, Prof ++49 421 497 ext 5240 bernd.hertenstein@klinikum-bremen-mitte.de BAG / Onkologische Gemeinschaftspraxis Recruiting Dresden, Germany, 01307 Contact: Thomas Illmer, PD Dr. ++49 351 44000 ext 22 illmer@onkologie-dresden.net Contact: Jens Freiberg-Richter, Dr. med. ++49 351 44000 ext 22 freiberg-richter@onkologie-dresden.net Universitätsklinikum Düsseldorf Recruiting Dusseldorf, Germany, 40225 Contact: Norbert Gattermann, Prof +49 211- 81 ext 16500 gattermann@med.uni-duesseldorf.de Contact: Judith Strapatsas (née Neukirchen), MD +49 211- 81 ext 17720 judith.strapatsas@med.uni-duesseldorf.de Principal Investigator: Norbert Gattermann, Prof Universitätsklinikum Erlangen Recruiting Erlangen, Germany, 91054 Contact: Stefan Krause, Prof ++49 9131 85 ext 35957 stefan.krause@uk-erlangen.de Contact: Norbert Meidenbauer, PD, MD ++49 9131 85 ext 36766 norbert.meidenbauer@uk-erlangen.de Principal Investigator: Stefan Krause, Prof Universitätsklinikum Essen, Klinik für Hämatologie Recruiting Essen, Germany, 45147 Contact: Joachim Goethert, MD ++49 201 723 84 ext 729 joachim.goethert@uk-essen.de Contact: Maher Hanoun, MD 0201 723 83 ext 847 maher.hanoun@uk-essen.de Klinikum der Goethe Universität, Medizinische Klinik II Recruiting Frankfurt a. Main, Germany, 60590 Contact: Fabian Lang, Dr.med. ++49 69 6301 ext 4013 fabian.lang@kgu.de Contact: Jörg Chromik, Dr.med. ++49 69 6301 ext 6103 joerg.chromik@kgu.de Universitätsklinikum Hamburg Eppendorf Recruiting Hamburg, Germany, 20246 Contact: Philippe Schafhausen, Dr. med. +49 40 7410 ext 57122 schafhausen@uke.de Contact: Snjezana Janjetovic, Dr. med. +49 40 7410 ext 50661 s.janjetovic@uke.de Evangelische Krankenhaus Hamm gGmbH Recruiting Hamm, Germany, 59063 Contact: Elisabeth Lange, MD 0049 2381 90583 ext 25 marianne.david@valeo-kliniken.de Contact: Thomas Wehler, Prof. Dr. 0049 2381 589 ext 1863 onkologie.hamm@valeo-kliniken.de Onkologische Praxis Heilbronn Withdrawn Heilbronn, Germany, 74072 Universitätsklinikum Jena Recruiting Jena, Germany, 07740 Contact: Andreas Hochhaus, Prof +49 3641 932 ext 4200 Andreas.Hochhaus@med.uni-jena.de Contact: Thomas Schenk, MD +49 3641 939 ext 6661 thomas.schenk@med.uni-jena.de Principal Investigator: Andreas Hochhaus, Prof Universitätsklinikum Leipzig Recruiting Leipzig, Germany, 04103 Contact: Georg-Nikolaus Franke, MD ++49 341 97 ext 13020 Georg-Nikolaus.Franke@medizin.uni-leipzig.de Contact: Song-Yau Wang, MD ++49 341 97 ext 13030 song-yau.wang@medizin.uni-leipzig.de Principal Investigator: Georg-Nikolaus Franke, MD Johannes-Gutenberg-Universität III. Medizinische Klinik Recruiting Mainz, Germany, 55131 Contact: Thomas Kindler, PD, MD ++49 6131 17 ext 5046 thomas.kindler@unimedizin-mainz.de Contact: Markus Radsak, Prof ++49 6131 17 ext 5947 radsak@uni-mainz.de Principal Investigator: Thomas Kindler, PD, MD Universitätsmedizin Mannheim Recruiting Mannheim, Germany, 68169 Contact: Susanne Saussele, PD, MD ++49 621-383 ext 6966 Susanne.Saussele@medma.uni-heidelberg.de Contact: Henning Popp, MD ++49 621-383 ext 4115 henning.popp@medma.uni-heidelberg.de Principal Investigator: Susanne Saussele, PD, MD Universitätsklinikum Gießen und Marburg GmbH Recruiting Marburg, Germany, 35043 Contact: Andreas Burchert, Prof. +49 6421 586 ext 6511 burchert@staff.uni-marburg.de Contact: Stephan K. Metzelder, MD +49 6421 586 ext 2724 metzelde@med.uni-marburg.de Principal Investigator: Andreas Burchert, Prof. Universitätsklinikum Münster Recruiting Muenster, Germany, 48149 Contact: Eva Esseling, MD ++49 251 83 ext 52807 eva.esseling@ukmuenster.de Contact: Jan-Henrik Mikesch, MD ++49 251 83 ext 52818 Jan-Henrik.Mikesch@ukmuenster.de Principal Investigator: Eva Schmidt, MD III. Medizinischen Klinik TUM Klinikum rechts der Isar Recruiting Munich, Germany, 81675 Contact: Philipp Jost, PD, MD ++49 89 4140 ext 5941 philipp.jost@tum.de Contact: Stefanie Jilg, MD ++49 89 4140 ext 4111 stefanie.jilg@tum.de Principal Investigator: Philipp Jost, PD, MD Universitätsklinikum Tübingen Recruiting Tubingen, Germany, 72076 Contact: Robert Möhle, Prof ++40 7071-29 ext 83179 robert.moehle@med.uni-tuebingen.de Contact: Martin Sökler, MD ++40 7071-29 ext 80686 martin.soekler@med.uni-tuebingen.de Principal Investigator: Robert Möhle, Prof Universitätsklinikum Ulm Recruiting Ulm, Germany, 89081 Contact: Frank Stegelmann, MD ++49 731-500 ext 45521 frank.stegelmann@uniklinik-ulm.de Contact: Konstanze Döhner, Prof ++49 731-500 ext 45505 konstanze.doehner@uniklinik-ulm.de Principal Investigator: Frank Stegelmann, MD Universitätsklinikum Würzburg, Zentrum für Innere Medizin Recruiting Würzburg, Germany, 97080 Contact: Maria-Elisabeth Goebeler, Dr.med. ++49 931 201 ext 40966 goebeler_m@ukw.de Contact: Volker Kunzmann, Prof. Dr. med. ++49 931 201 ext 40004 kunzmann_v@ukw.de Less << |
| NCT00787761 | - | Completed | - | - | |
| NCT01660321 | Pediculosis | Phase 4 | Completed | - | United States, Arkansas ... More >> Burke Pharmaceutical Research Hot Springs, Arkansas, United States, 71913 United States, Florida Lice Solutions Resource Network, Inc. West Palm Beach, Florida, United States, 33407 Less << |
| NCT01544283 | Shoulder Pain | Phase 2 | Unknown | March 2014 | United States, Idaho ... More >> Injury Care Medical Center Recruiting Boise, Idaho, United States, 83713 Contact: Jill L Heinz, MHS, CCRP 208-939-2100 ext 4 jill@injurycaremedical.com Principal Investigator: Richard D Radnovich, DO Less << |
| NCT01660321 | - | Completed | - | - | |
| NCT02216838 | Facial Flushing | Not Applicable | Active, not recruiting | December 2018 | United States, Illinois ... More >> Northwestern University Feinberg School of Medicine, Department of Dermatology Chicago, Illinois, United States, 60611 Less << |
| NCT00873262 | Premenstrual Syndrome | Phase 2 | Unknown | November 2010 | Israel ... More >> Tel Aviv Sourasky Medical Center Recruiting Tel Aviv, Israel, 64239 Contact: Shmuel Kivity, Prof. +972-3-697-3734 allergy@tasmc.health.gov.il Contact: Tzipi Yemini +972-3-697-3734 zipiy@tasmc.health.gov.il Principal Investigator: Shmuel Kivity, Prof. Less << |
| NCT00951743 | HIV Infections | Phase 2 | Unknown | July 2010 | United States, District of Col... More >>umbia Whitman Walker Clinic Recruiting Washington, District of Columbia, United States, 20009 Principal Investigator: Richard Elion, MD Less << |
| NCT00356200 | Psoriasis | Phase 2 | Terminated(Enrollment criteria... More >> met) Less << | - | United States, Massachusetts ... More >> Tufts-New England Medical Center Boston, Massachusetts, United States, 02111 Less << |
| NCT00866437 | Premenstrual Syndrome | Phase 2 | Unknown | November 2010 | Israel ... More >> Sheba Medical Center, Tel-Hashomer Recruiting Ramat Efal, Israel, 52621 Contact: Avner Reshef, Dr +972-3-5302605 Avner.Reshef@sheba.health.gov.il Contact: Iris Leibovich +972-3-5302605 iris.leibovich@sheba.health.gov.il Principal Investigator: Avner Reshef, Dr Less << |
| NCT02677610 | Atopic Dermatitis | Phase 3 | Withdrawn | March 2017 | - |
| NCT00439374 | Preterm Delivery ... More >> Cervical Length Less << | Phase 3 | Terminated(Halted by NICHD aft... More >>er recommendation by DSMC to stop for futility) Less << | - | United States, Alabama ... More >> University of Alabama - Birmingham Birmingham, Alabama, United States, 35429 United States, Illinois Northwestern University-Prentice Hospital Chicago, Illinois, United States, 60611 United States, Michigan Dept of OB/GYN, Hutzel Hospital Detroit, Michigan, United States, 48201 United States, New York Columbia University-St. Luke's Hospital New York City, New York, United States, 10032 United States, North Carolina University of North Carolina - Chapel Hill Chapel Hill, North Carolina, United States, 27599 United States, Ohio Case Western Reserve-Metrohealth Cleveland, Ohio, United States, 44109 Ohio State University Hospital Columbus, Ohio, United States, 43210 United States, Oregon Oregon Health & Sciences University Portland, Oregon, United States United States, Pennsylvania University of Pittsburgh-Magee Womens Hospital Pittsburgh, Pennsylvania, United States, 15213 United States, Rhode Island Brown University -Women and Infants Hospital Providence, Rhode Island, United States, 02095 United States, Texas Dept of OB/GYN, Southwestern Medical Center, University of Texas Dallas, Texas, United States, 75235-9032 University of Texas Medical Branch - Galveston Galveston, Texas, United States, 77555 University of Texas-Houston Houston, Texas, United States United States, Utah University of Utah Medical Center Salt Lake City, Utah, United States, 84132 Less << |
| NCT02677636 | Atopic Dermatitis | Phase 3 | Withdrawn | - | - |
| NCT03502434 | Tendinopathy | Phase 1 | Completed | - | United States, Virginia ... More >> Research Site Lynchburg, Virginia, United States, 24503 Less << |
| NCT00693654 | Pruritis | Phase 4 | Completed | - | United States, North Carolina ... More >> Wake Forest University Health Sciences Dermatology Winston-Salem, North Carolina, United States, 27157 Less << |
| NCT00693654 | - | Completed | - | - | |
| NCT01175759 | Abortion, Recurrent | Phase 2 | Unknown | December 2011 | Hungary ... More >> Depts. Gynecology and Obstetrics and 3rd Dept of Internal Medicine Recruiting Budapest, Hungary, H1125 Contact: George Füst, Prof. 361-212-9351 fustge@kut.sote.hu Principal Investigator: János Rigó, Prof. Principal Investigator: Henriette Farkas, Prof. Less << |
| NCT01759459 | Pain Local An... More >>esthesia for Peripheral Intravenous Catheterization Less << | Phase 4 | Completed | - | United States, Minnesota ... More >> United Hospital, part of Allina Health Services Saint Paul, Minnesota, United States, 55102 Less << |
| NCT02407340 | Alcoholism Al... More >>cohol Related Disorders Less << | Phase 1 | Completed | - | United States, Maryland ... More >> Johns Hopkins University Baltimore, Maryland, United States, 21205 Less << |
| NCT02162680 | IV Insertion Pain | Phase 4 | Completed | - | - |
| NCT00000645 | HIV Infections | Phase 1 | Completed | - | United States, Massachusetts ... More >> Beth Israel Deaconess - East Campus A0102 CRS Boston, Massachusetts, United States, 02215 United States, Minnesota University of Minnesota, ACTU Minneapolis, Minnesota, United States United States, New York NY Univ. HIV/AIDS CRS New York, New York, United States, 10016 Less << |
| NCT02162680 | - | Completed | - | - | |
| NCT02010333 | Head Lice Infestation | Phase 2 | Completed | - | United States, California ... More >> Universal Biopharma Research Institute Dinuba, California, United States, 93618 Axis Clinical Trials Los Angeles, California, United States, 90036 Less << |
| NCT01353313 | Infant, Newborn ... More >> Infant, Small for Gestational Age Infant, Very Low Birth Weight Infant, Premature Bronchopulmonary Dysplasia Less << | Phase 3 | Recruiting | January 2025 | United States, Alabama ... More >> University of Alabama at Birmingham Recruiting Birmingham, Alabama, United States, 35233 Contact: Waldemar A. Carlo, MD Principal Investigator: Waldemar A. Carlo, MD United States, California University of California - Los Angeles Active, not recruiting Los Angeles, California, United States, 90025 Stanford University Recruiting Palo Alto, California, United States, 94304 Contact: Krisa P. Van Meurs, MD Principal Investigator: Krisa P. Van Meurs, MD United States, Georgia Emory University Recruiting Atlanta, Georgia, United States, 30303 Contact: David P Carlton, MD Principal Investigator: David P Carlton, MD United States, Indiana Indiana University Active, not recruiting Indianapolis, Indiana, United States, 46202 United States, Iowa University of Iowa Recruiting Iowa City, Iowa, United States, 52242 Contact: Edward F. Bell, MD Principal Investigator: Edward F. Bell, MD United States, Michigan Wayne State University Active, not recruiting Detroit, Michigan, United States, 48201 United States, Missouri Children's Mercy Hospital Active, not recruiting Kansas City, Missouri, United States, 64108 United States, New Mexico University of New Mexico Recruiting Albuquerque, New Mexico, United States, 87131 Contact: Kristi L. Watterberg, MD Principal Investigator: Kristi L. Watterberg, MD United States, New York University of Rochester Recruiting Rochester, New York, United States, 14642 Contact: Carl T D'Angio, MD Principal Investigator: Carl T D'Angio, MD United States, North Carolina RTI International Active, not recruiting Durham, North Carolina, United States, 27705 Duke University Recruiting Durham, North Carolina, United States, 27710 Contact: C. Michael Cotten, MD Sub-Investigator: C. Michael Cotten, MD MHS United States, Ohio Cincinnati Children's Medical Center Recruiting Cincinnati, Ohio, United States, 45267 Contact: Brenda Poindiexter, MD Principal Investigator: Brenda Poindexter, MD Case Western Reserve University, Rainbow Babies and Children's Hospital Recruiting Cleveland, Ohio, United States, 44106 Contact: Michele C. Walsh, MD MS Principal Investigator: Michele C. Walsh, MD MS Research Institute at Nationwide Children's Hospital Recruiting Columbus, Ohio, United States, 43205 Contact: Pablo Sanchez, MD Principal Investigator: Pablo Sanchez, MD United States, Pennsylvania Univeristy of Pennsylvania Recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: Eric Eichenwald, MD Principal Investigator: Eric Eicenwald, MD United States, Rhode Island Brown University, Women & Infants Hospital of Rhode Island Recruiting Providence, Rhode Island, United States, 02905 Contact: Abbot R. Laptook, MD Principal Investigator: Abbot R. Laptook, MD United States, Texas University of Texas Southwestern Medical Center at Dallas Recruiting Dallas, Texas, United States, 75235 Contact: Myra Wyckoff, MD Principal Investigator: Myra Wyckoff, MD University of Texas Health Science Center at Houston Recruiting Houston, Texas, United States, 77030 Contact: Jon E Tyson, MD MPH Principal Investigator: Jon E. Tyson, MD MPH United States, Utah University of Utah Recruiting Salt Lake City, Utah, United States, 84108 Contact: Bradley Yoder, MD Principal Investigator: Bradley A. Yoder, MD Less << |
| NCT01937494 | Asthma Bronch... More >>ial Hyperresponsiveness Less << | Not Applicable | Completed | - | Belgium ... More >> service de pneumologie, CHU St Pierre Brussels, Belgium, 1000 Less << |
| NCT02209272 | Hip Pain | Phase 4 | Completed | - | United States, Minnesota ... More >> Mayo Clinic in Rochester Rochester, Minnesota, United States, 55905 Less << |
| NCT00259350 | ICU Patients Requiring a Centr... More >>al Venous Access Less << | Phase 4 | Completed | - | France ... More >> University hospital Poitiers, Vienne, France, 86021 Less << |
| NCT02018250 | Treatment Against the Lethal E... More >>ffects of Nerve Agent Intoxication Less << | Phase 1 | Completed | - | United States, Maryland ... More >> SNBL Clinical Pharmacology Center, Inc. Baltimore, Maryland, United States, 21201 Less << |
| NCT01954056 | Infant, Newborn, Diseases ... More >> Cardiovascular Insufficiency Less << | Phase 3 | Completed | - | United States, Alabama ... More >> University of Alabama at Birmingham Birmingham, Alabama, United States, 35233 United States, California University of California - Los Angeles Los Angeles, California, United States, 90025 Stanford University Palo Alto, California, United States, 94304 United States, Georgia Emory University Atlanta, Georgia, United States, 30303 United States, Indiana Indiana University Indianapolis, Indiana, United States, 46202 United States, Iowa University of Iowa Iowa City, Iowa, United States, 52242 United States, Michigan Wayne State University Detroit, Michigan, United States, 48201 United States, Missouri Children's Mercy Hospital Kansas City, Missouri, United States, 64108 United States, New Mexico University of New Mexico Albuquerque, New Mexico, United States, 87131 United States, New York University of Rochester Rochester, New York, United States, 14642 United States, North Carolina RTI International Durham, North Carolina, United States, 27705 Duke University Durham, North Carolina, United States, 27710 United States, Ohio Cincinnati Children's Medical Center Cincinnati, Ohio, United States, 45267 Case Western Reserve University Cleveland, Ohio, United States, 44106 Research Institute at Nationwide Children's Hospital Columbus, Ohio, United States, 43205 United States, Pennsylvania University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 United States, Texas University of Texas Southwestern Medical Center at Dallas Dallas, Texas, United States, 75235 University of Texas Health Science Center at Houston Houston, Texas, United States, 77030 Less << |
| NCT02573025 | Healthy Volunteers | Phase 1 | Completed | - | Australia, South Australia ... More >> CMAX A division of IDT Australia Limited Adelaide, South Australia, Australia, 5000 Hong Kong The University of Hong Kong; Pharmacy Clinical Trials Hong Kong, Hong Kong The Chinese University of Hong Kong; Emergency Medicine Shatin, Hong Kong, 00000 New Zealand Christchurch Clinical Studies Trust Christchurch, New Zealand, 8011 Auckland Clinical Studies Limited Grafton, New Zealand, 1010 Singapore SingHealth Investigational Medicine Unit; Haematology Singapore, Singapore, 169608 Changi General Hospital- Parent; Department of Rheumatology Singapore, Singapore, 529889 Taiwan China Medical University Hospital;Oncology and Hematology Office Critical Care Center, 14H Taichung, Taiwan, 404 Taipei Medical University Hospital; Clinical Research Center Taipei City, Taiwan, 110 Less << |
| NCT01907490 | - | Completed | - | - | |
| NCT01907490 | Head Lice Infestation | Phase 2 | Completed | - | - |
| NCT02485717 | Scabies | Phase 3 | Completed | - | United States, California ... More >> Elk Grove Clinical Research Elk Grove, California, United States, 95758 United States, Florida The Chappel Group Research Kissimmee, Florida, United States, 34744 San Marcus Research Miami, Florida, United States, 33015 L&C Professional Medical Research Institute Miami, Florida, United States, 33144 LSRN Research West Palm Beach, Florida, United States, 33407 United States, Washington Mid Columbia Research Richland, Washington, United States, 99352 Less << |
| NCT02624843 | Head Lice | Phase 3 | Completed | - | United States, California ... More >> Axis Clinical Trials Los Angeles, California, United States, 90017 Axis Clinical Trials Los Angeles, California, United States, 90036 United States, Florida South Florida Family Health and Research Centers (Lice Source Services Inc) Miami, Florida, United States, 33186 South Florida Family Health and Research Centers (Lice Source Services Inc) Plantation, Florida, United States, 33313 Less << |
| NCT02545712 | - | Active, not recruiting | - | - |
| Bio Calculators | ||||
| Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
9.25mL 1.85mL 0.92mL |
46.24mL 9.25mL 4.62mL |
92.47mL 18.49mL 9.25mL |
|
| Dissolving Methods |
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:
in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
|
|||